Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Defining Reversal of Alopecia Areata (AA) Phenotype With Dupilumab in Patients With and Without Associated Atopic Dermatitis (AD)
Brief Summary: Alopecia areata is a medical condition, in which the hair falls out in patches. The hair can fall out on the scalp or elsewhere on the face and body. Alopecia areata is an autoimmune skin disease, which means that the immune system is recognizing the hair follicles as foreign and attacking them, causing round patches of hair loss. It can progress to total scalp hair loss (alopecia totalis) or complete body hair loss (alopecia universalis). The scalp is the most commonly affected area, but the beard or any hair-bearing site can be affected alone or together with the scalp. Alopecia areata occurs in males and females of all ages, and is a highly unpredictable condition that tends to recur. Alopecia areata can cause significant distress to both patients and their families. In this study, the aim is to assess the effects of dupilumab in patients with alopecia areata.


Options:
A: Arm Label: Dupilumab; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dupilumab; Assigned to Arm(s): Dupilumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Hydrocortisone 1%; Type: EXPERIMENTAL; Interventions: Drug: Hydrocortisone 1% | Arm Label: Clobetasol Propionate 0.05%; Type: EXPERIMENTAL; Interventions: Drug: Clobetasol Propionate 0.05% | Intervention Type: DRUG; Name: Hydrocortisone 1%; Assigned to Arm(s): Hydrocortisone 1% | Intervention Type: DRUG; Name: Clobetasol Propionate 0.05%; Assigned to Arm(s): Clobetasol Propionate 0.05%
C: Arm Label: 4 Milligram (mg) Baricitinib; Type: EXPERIMENTAL; Interventions: Drug: Baricitinib, Drug: Placebo | Arm Label: 2 mg Baricitinib; Type: EXPERIMENTAL; Interventions: Drug: Baricitinib, Drug: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 4 mg Baricitinib Maximum Extended Enrollment (MEE); Type: EXPERIMENTAL; Interventions: Drug: Baricitinib, Drug: Placebo | Arm Label: 2 mg Baricitinib MEE; Type: EXPERIMENTAL; Interventions: Drug: Baricitinib | Arm Label: Placebo MEE; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Baricitinib; Assigned to Arm(s): 2 mg Baricitinib, 2 mg Baricitinib MEE, 4 Milligram (mg) Baricitinib, 4 mg Baricitinib Maximum Extended Enrollment (MEE) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 mg Baricitinib, 4 Milligram (mg) Baricitinib, 4 mg Baricitinib Maximum Extended Enrollment (MEE), Placebo, Placebo MEE
D: Arm Label: Baricitinib High Dose; Type: EXPERIMENTAL; Interventions: Drug: Baricitinib, Drug: Placebo | Arm Label: Baricitinib Low Dose; Type: EXPERIMENTAL; Interventions: Drug: Baricitinib, Drug: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Open-Label Addenda Baricitinib High Dose; Type: EXPERIMENTAL; Interventions: Drug: Baricitinib | Intervention Type: DRUG; Name: Baricitinib; Assigned to Arm(s): Baricitinib High Dose, Baricitinib Low Dose, Open-Label Addenda Baricitinib High Dose | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Baricitinib High Dose, Baricitinib Low Dose, Placebo

Answer: A